baber/WOPTO huggingface dataset:
Patent PT-1042746-E (PT)
Inventor: AGRAIVES BERTRAND CAUSSE D
IPC: G09F3/03
Filed: 1998-12-21
Abstract: The invention concerns a method for making identity cores for ultrasound seals. Each core comprises a chip consisting of a brazed stack of metal disks 1 bearing at least one notch 3, the resulting identity being defined by the number, the size and the random angular position of the various notches in the stack and by the unpredictability of the brazing. The invention is characterized in that the notched disks 1 provided with a central hole 2 are first stacked in large numbers in a tubular metal sheath 4 with a circular cross-section corresponding to said disks 1. The stack is then axially compressed in the sheath 4 and a brazing bead 7 is inserted in the channel constituted by the assembly of aligned central holes 2. After brazing in a vacuum oven, the two ends of the sheath are eliminated and the resulting column is segmented perpendicularly to its axis into a series of individual identity chips 8 of predetermined thickness. Such a chip is finally associated by brazing with a metal block 13 used as delay line to constitute the core. Identity control can be combined with integrity control by associating an integrity rod 10 to 12 with said block 13, whereby with one reading both identity and integrity can be ascertained.
Patent PT-997515-E (PT)
Inventor: GOODHUE K GIFFORD JR
IPC: C09K17/22
Filed: 1996-01-19
Abstract: This invention relates to an earth stabilization fluid and to a method for using such an earth stabilization fluid. This invention uses a continuous phase that has been added to a borehole and a polymer material that forms gel masses having desired functional properties when added to the continuous phase.
Patent PT-983777-E (PT)
Inventor: SARDO ALBERTO
IPC: A62D3/37
Filed: 1999-08-20
Abstract: A method for post-harvest treatment of fruit and vegetables uses a composition prepared by purifying a phytosanitary product (I) contaminated with aromatic primary amines and mixing the resulting reaction mixture with water. A method for post-harvest treatment of fruit and vegetables uses a composition prepared by purifying a phytosanitary product (I) contaminated with aromatic primary amines and mixing the resulting reaction mixture with water. The purification process comprises: (1) stirring a solution of (I) in a nonionic surfactant and/or a 2-12C glycol with an aqueous alkali metal nitrite solution at 15-25 degrees C; (2) adding a strong mineral acid to the mixture while stirring at the same temperature; and (3) heating the mixture to 30-70 degrees C.
Patent PT-1094890-E (PT)
Inventor: RAAIJMAKERS HENRICUS WILHELMUS
IPC: C09K23/56
Filed: 1999-06-09
Abstract: Dispersions of pigment, such as calcium carbonate, titanium dioxide and types of clay, can be effectively stabilized by the use of carboxyl-containing fructan in an amount of 0.05-10% by weight, based on the dispersion, which fructan contains 0.5-3 carboxyl groups per mono-saccharide unit. The carboxyalkyl groups are in particular carboxymethyl groups, but the carboxyl groups can also be carboxyl groups obtained entirely or partially by oxidation. The carboxymethylfructan gives results which are comparable to or better than those obtained with the polyacrylates which are less desirable from the standpoint of health and environment.
Patent PT-1140023-E (PT)
Inventor: DAVID MARGOLIS
IPC: C12N15/88
Filed: 1999-12-13
Abstract: An integrative DNA vector and one or more viral proteins having affinity for DNA are packaged in cochleate precipitates. The integrative DNA vector contains one or more therapeutic nucleotide sequences that are preferably positioned between DNA substrates for the proteins. Upon contact with a lipid bilayer of a target cell, the cochleate vector structure delivers one or more of the therapeutic nucleotide sequences and one or more proteins to the interior of the target cell. Upon entry into the cell, the proteins facilitate the integration of the therapeutic nucleotide sequence into the genome of the host cell.
Patent CA-2738767-F (CA)
Title: Profiled key for cylinder locks
Inventor: WIDEN BO
IPC: E05B27/10
Filed: 2010-01-04
Granted: 2010-08-26
Abstract: A key for use in a cylinder lock with a rotatable key plug having a profiled keyway. The key comprises an elongated, substantially flay key blade (120; 120') having a longitudinal profile groove (122; 122') extending along at least a portion of the length of the key blade. The groove has an undercut portion (129) adjacent to a ridge portion (128, 128'), the outside of which forms part of a side surface (123; 123') of the key blade and the inside of which comprises a side wall portion (126; 126') being inclined and facing the bottom wall (124; 124') of the groove. The undercut portion (129; 129') of the groove is expanded, at its innermost part adjacent to said inclined side wall portion (126; 126'), into a longitudinally extending pocket (135; 135').
Patent SG-97790-G (SG)
Title: Stabilized sodium erythorbate and its use as a corrosion inhibitor
IPC: C23F11/12
Filed: 1990-12-10
Abstract: A method for inhibiting corrosion due to dissolved oxygen comprises adding chelant-stabilized sodium erythorbate, alone or in combination with conventional corrosion inhibitors, to boiler water to prevent corrosion by reducing dissolved oxygen levels in boiler feedwater. Novel compositions contain sodium erythorbate and, as chelant, nitrilotriacetic acid, ethylenediamine tetraacetic acid, N-hydroxyethyl) ethylenediamine triacetic acid or citric acid, or a salt of such an acid.
Patent IE-900067-L (IE)
Title: Novel tetralin derivatives
IPC: A61K31/135
Filed: 1990-01-08
Abstract: This invention relates to novel derivatives of tetralin, to the processes for their preparation, to their use as aminopeptidase inhibitors and to their end-use application as immunomodulators and as analgesic agents.
[EP0378456A1]
Patent IE-900260-L (IE)
Title: Derivatives of benzocycloalkenyldihydroxyalkanoic acids,¹processes of preparation and medications containing them
IPC: C07D311/04
Filed: 1990-01-23
Abstract: Derivatives of benzocycloalkenyldihydroxyalkanoic acids, inhibitors of HMG CoA reductase, antagonists of thromoboxane A2 receptors and antifungals, denoted by the formula I 1 in which X=CH2, O or S; R1 and R2, identical or different, =H, C1-3 alkyl or together from a -(CH2)n- chain (n=4,5) optionally substituted symmetrically by one or two C1-3 alkyl radicals. R3 and R4, identical or different, =H, CF3, halogen (Cl, F, Br), C1-5 N,N-dialkylamino, C1-4 alkyl, C1-5-alkoxy, C1-3 alkylthio, or phenyl optionally substituted by at most two substitutents which may be identical or different and may denote C1-3 alkyl or C1-3 alkoxy radicals or halogens (F, Cl), it being understood that when one of R3 and R4 denotes the radicals: CF3, N,N-dialkylamino, C6H5 or substituted phenyl, it is present at the vertices 3', 4'or 5' according to formula 1 and the other denotes a hydrogen atom. R5 and R6, (which may be identical or different)=H, halogen (F, Cl, Br), CF3, C1-3 alkyl, C1-3 alkoxy, C6H5, optionally substituted by at most two substitutents which may be identical or different and may denote radicals: C1-3 alkyl or C1-3 alkoxy or halogen atoms (F, Cl), on condition that when one of R5 and R6=CF3, C6H5 or substituted phenyl, it is present at the vertex 6 or 7 and the other denotes a hydrogen atom. The substitutents R3 and R4 or R5 and R6 may also together form, on condition of being at two contiguous vertices, diradicals of formulae: -CH=CH-CH=CH-, -(CH2)m- and -O(CH2)pO-, in which m=3 or 4, p=1 or 2, it being understood that when R3 and R4 or R5 and R6 form the chain sequence -O(CH2)pO-, the latter is linked to the vertices 3' and 4' or 4' and 5' or 6 and 7 according to the formula 1. R7 and R8=H or, together with the existing C-C bond, form a double bond of trans geometry; R9 and R10=H or together form a C1-3 dialkylmethylene residue. In the form of free acids, salts, esters, amides or delta -lactones. Hypocholesterolaemiant, antithrombotic and antifungal medications containing them.
Patent IE-40601-L (IE)
Title: Determining antigens by immunoelectrophoresis¹¹immuno-electrophoresis
IPC: G01N33/561
Filed: 1975-02-13
Abstract: An arrangement for the simultaneous qualitative or quantitative determination of several antigens in mixtures of antigens by immunoelectrophoresis in a matrix containing antibodies, by coating the support for the matrix with several matrix strips, one following the other and each containing a specific antiserum, and a process for the determination of several antigens in mixtures, wherein said arrangement is used.[US3930983A]
Patent IE-34053-L (IE)
Title: Phenylcarbamates
IPC: C07C239/00
Filed: 1970-03-10
Abstract: 1308183 Phenyl carbamates SCHERING AG 11 March 1970 [11 March 1969] 11672/70 Heading C2C The invention comprises compounds of the Formula I where R 1 and R 2 each represents an optionally substituted aliphatic, cycloaliphatic, aromatic or araliphatic hydrocarbon group, R 1 may also represent a hydrogen atom or R 1 , R 2 and the carbon atom to which they are attached represent an optionally substituted cycloaliphatic radical, R 3 is an optionally substituted aliphatic, cycloaliphatic aromatic or araliphatic group, an alkoxy or aryloxy group or a group of the formula -NR<SP>1</SP> 1 R<SP>1</SP> 2 or where R<SP>1</SP> 1 and R<SP>1</SP> 2 each represents an optionally substituted aliphatic, cycloaliphatic, aromatic or araliphatic hydrocarbon group or a heterocyclic group, R<SP>1</SP> 1 may also represent a hydrogen atom and R<SP>1</SP> 2 may also represent an aliphatic hydrocarbon group substituted by a heterocyclic radical, or R<SP>1</SP> 1 , R<SP>1</SP> 2 and the nitrogen atom to which they are attached may represent a heterocyclic group optionally containing at least one further nitrogen and/or oxygen atom, R<SP>11</SP> 1 and R<SP>11</SP> 2 each represents an optionally substituted aliphatic, cycloaliphatic, aromatic or araliphatic hydrocarbon group, R<SP>11</SP> 1 may also represent a hydrogen atom or R<SP>11</SP> 1 and R<SP>11</SP> 2 together with the carbon atom to which they are attached represent an optionally substituted cycloaliphatic hydrocarbon group, and R 4 and R 5 each represents a hydrogen atom or an aliphatic hydrocarbon group. They are prepared by reacting a compound of formula with (i) R<SP>1</SP> 1 R<SP>1</SP> 2 N-CO-hal, or where hal is a halogen atom and R<SP>1</SP> 3 is an optionally substituted aliphatic, cycloaliphatic, aromatic or araliphatic hydrocarbon group or an alkoxy or aryloxy group or with (ii) phosgene or thiophosgene in the presence of an acidbinding agent and either an amine HNR<SP>1</SP> 1 R<SP>1</SP> 2 or an alcohol R<SP>1</SP> 3 OH where R<SP>1</SP> 3 is as defined above or an oxime HO-N-CR<SP>11</SP> 1 R<SP>11</SP> 2 , or (iii) with an isocyanate R 3 -N=C=O where in Formula I R 3 represents NR<SP>1</SP> 1 R<SP>1</SP> 2 . The compounds have herbicidal activity. Compounds of Formula II are prepared from aminophenols and chloroformic acid esters of oximes.
[GB1308183A]
Patent IE-34071-L (IE)
Title: Diamond compacts
IPC: B24D3/14
Filed: 1970-04-10
Abstract: 1307713 Abrasive articles MEGADIAMOND CORP 9 April 1970 [17 April 1969] 16845/70 Heading C4V A rigid diamond compact consists of discrete diamond particles bonded together by not exceeding an equal volume of a non-diamond abrasive substance having a Knoop (100 gram.) hardness of at least 1000. The bonding abrasive may be boron carbide, silicon carbide, titanium carbide, titanium boride, aluminium boride, silicon boride, zirconium carbide, aluminium carbide, aluminium oxide, tungsten carbide, boron nitride, hafnium carbide, niobium carbide, silicon nitride, beryllium carbide, vanadium carbide, silicon, tantalum boride, vanadium boride, beryllium oxide, magnesium oxide, aluminium nitride or boron phosphide. The diamond particles may be less than 325 mesh United States Standard particle size. The materials may be made by subjecting a mixture of the diamond particles and the abrasive or a progenitor of such a substance to a temperature of at least 900 K. and a pressure of not less than 10 kilobars at which diamond is crystallographically stable.
[GB1307713A]
Patent IE-37491-L (IE)
Title: 6 - [ó-(guanylureidoalkanoylamino) aracylamino] penicillanic¹acids
IPC: A61P31/04
Filed: 1973-04-03
Abstract: 1404469 Peptide derivatives of penicillanic acids PFIZER Inc 11 Sept 1972 [16 May 1972] 42179/72 Heading C3H [Also in Division C2] Per se compounds of formula wherein Ar is phenyl, 4-hydroxyphenyl, 2- thienyl or 3-thienyl; A is alkylene or alkylidener, n is 1-3; R 1 , R 2 , R 3 and R 4 are each H or alkyl, or R 1 and R 4 , R 2 and R 4 , R 2 and R 3 taken together are alkylene. The following intermediates are prepared: 3 - guanyl - 1 - ureidoacetylglycylglycine hydrochloride by the reaction of glycylglycylglycine with 3 - guanyl - 1 - nitrourea, followed by treatment with hydrogen chloride gas. Peptide intermediates of formula are prepared by the reaction of the appropriate dipeptide or tripeptide with (1)-(7) the requisite 3-guanyl-1-nitrourea (8)-(9) the requisite guanylureidoalkanoyl chloride; the substituents being
[GB1404469A]
Patent IE-800695-L (IE)
Title: Power generating system utilising ambient heat
IPC: F01K25/10
Filed: 1980-04-03
Abstract: A power system is provided that uses the latent heat of fusion of water to raise the potential energy of a working fluid to a level that upon release generates power, preferably electrical power. The system is self-sustaining except for the energy that is supplied in water entering the system. The inlet water can be at any temperature within its liquid range under atmospheric or super atmospheric pressure, can advantageously contain the sensible waste heat typical of effluent from fossil fuel or nuclear power plants, can be relatively pure or be contaminated as with sewage or be the medium of a colloidal suspension, or consist of marine or other saline waters. In every case, purification of the water by freezing, for example, desalination, is accomplished without additional power consumption. A selected working fluid that boils at a temperature substantially below the freezing point of water is brought in the liquid state into contact with the water or other aqueous medium, causing the water to freeze and the working fluid to vaporize under pressure; the produced ice is removed; a portion of the so-produced ice is admixed with a eutectic forming salt to create a cooling medium at a temperature below the condensation temperature of the cooling fluid; the working-fluid vapors are preferably superheated by inlet aqueous medium and are released from autogenic elevated pressure to drive a turbine. Working fluid vapors are condensed by said cooling medium and returned by pumping into contact with inlet aqueous medium.
[US4283211A]
Patent IE-36434-L (IE)
Title: Gentamicin antibiotics.
IPC: C07H/
Filed: 1971-06-21
Abstract: 1355260 Gentamicin antibiotics SCHERICO Ltd 21 June 1971 [22 June 1970] 28962/71 Heading C2A The novel antibiotics gentamicin B, gentamicin B 1 and gentamicin X, and the known antibiotic gentamicin A, having the general Formula (II) wherein R 1 , R 2 , R 3 and R 4 are as follows: and salts and solvates thereof, are produced by subjecting a mixture of the said antibiotics (e.g. the fermentation products of Micromonospora purpurea or Micromonospora echinospora) to chromatography, suitably on silica gel developing with methanol, chloroform and ammonium hydroxide, and recovering the fractions containing each antibiotic. The fermentation products may be initially adsorbed on a cation exchange resin and eluted with ammonium hydroxide, decolorized on charcoal and the solution concentrated in vacuo to provide the starting mixture for the present process. The mixture may be further pretreated, e.g. by adsorption on anion exchange resin, eluting with water to remove gentamicin C, followed by further elution with water to obtain the desired mixture. The mixture is chromatographed on a silica gel column using as developing solvent the lower layer of a mixture of methanol, chloroform and ammonium hydroxide (1 : 1 : 1 v/v), whereby the antibiotics are eluted in the order: gentamicin B 1 , X, B and finally A. The antibiotics may be isolated by lyophilization, and may be recrystallized from ethanol, when they are obtained as the ethanol solvates. When obtained from aqueous solutions, they are in the form of hydrates. Gentamicin A may be obtained as the carbonate salt by exposing the methanolic solution to air, resulting in absorption of CO 2 and precipitation of the said carbonate salt. The antibiotics may be converted to other acid-addition salts by conventional procedures. Gentamicins A, B, B 1 and X have antibiotic activity against Gram-positive and -negative micro-organisms and in addition have antiprotozoal and anthelmintic activity. They may be used individually or together, optionally with a pharmaceutical carrier, in pharmaceutical compositions having corresponding activity.
[GB1355260A]
Patent IE-38059-L (IE)
Title: Hollow clayware.
IPC: B28B21/92
Filed: 1973-06-12
Abstract: 1390965 Sizing hollow clay articles HEPWORTH IRON CO Ltd 6 June 1973 [15 June 1972] 28091/72 Heading B5A [Also in Division C7] A mandrel having a co-efficient of expansion greater than fired clay is inserted within a hollow, unfired clay article, and the clay then fired. On cooling, the mandrel shrinks away from the clay to allow removal. As described, undersized steel mandrels 20, 22 are inserted one in each end of a moulded or extruded green clay pipe 10. The clay is heated up to 200 C. to reduce its moisture content to 1%, either supported on rings 18, 20 on a kiln car within an associated drying chamber, or on a roller drier conveyer. The clay is then fired at 1040 C., and becomes plastic and contracts on to the mandrels as the maximum temperature is reached. The clay is freeze-cooled by blown air to reduce the temperature to 700 C., when the mandrels can be removed. The mandrels can be inserted into the pipe at any time up to the clay becoming plastic. An iron/chromium/silicon ferritic alloy is described for the mandrel, having magnetic properties to aid insertion and removal. Spigots, sockets, and plain pipe ends can be sized.
[GB1390965A]
Patent FI-810548-L (FI)
Inventor: JAERVENPAEAE VILJO JUHANA
IPC: B01D53/18
Filed: 1981-02-23
Abstract: The invention concerns a means for removing gaseous components and/or solid impurities present in a gaseous fluid flow. The means (10) comprises a frame structure (11, 12), a fluid flow inlet connector (13), disposed within the frame structure (11, 12) a scrubber means (15), an exit connector (14) for carrying off the purified fluid flow, and a connector (20) for introducing scrubbing liquid into the means (10) and contacting it with the fluid flow. The scrubbing liquid exit flow has been disposed to pass through the fluid flow inlet connector (13) in opposite direction with reference to the fluid flow. The end region (21) adjacent to the scrubber means (15) of the fluid flow inlet connector (13) has a diminishing cross sectional diameter to the purpose of accelerating the flowing fluid flow before the fluid flow enters the scrubber means (15). The inlet connector (13) has been provided with holes (22) which have been adapted to receive into the inlet connector (13) the return flow of the scrubbing liquid. The holes (22) have been disposed in that region of the inlet connector (13) where the flow of the fluid flow is not accelerated, whereby the scrubbing liquid return flow within the inlet connector (13) is prevented from being entrained with the fluid flow and produces pre-purification of the fluid flow.
Patent FI-824404-L (FI)
Inventor: LEGERIUS BENGT
IPC: H02G3/22
Filed: 1982-12-21
Abstract: PCT No. PCT/SE82/00133 Sec. 371 Date Dec. 15, 1982 Sec. 102(e) Date Dec. 15, 1982 PCT Filed Apr. 23, 1982 PCT Pub. No. WO82/03951 PCT Pub. Date Nov. 11, 1982.A method and tool for sealingly inserting an elastic body in a cavity in a wall in which the cavity has a smaller size than the initial size of the body. A first tubular end portion of the tool is inserted into the cavity and an elastic body is accommodated in a second larger tubular end portion of the tool such that the elastic body rests on a tapered portion which joins the tubular end portions. The second tubular end portion is then closed and pressure fluid is supplied into the second tubular end portion to compress the elastic body and cause it to pass from the second tubular portion into the first tubular portion and then to exit from the first tubular portion into the cavity. The elastic body expands as it exits from the first tubular portion to tightly engage the wall around the cavity and to expel the first tubular end portion from the cavity.
Patent IE-831133-L (IE)
Title: Methods for the preparation of biotin and intermediates¹therefor
IPC: C07D495/04
Filed: 1983-05-16
Abstract: A novel process is described for preparation of biotin comprising preparation of substituted 3H, 5H-imidazo[1, 5c]tetrahydro thiazoles by contacting the boron trifluoride adduct of an appropriate thiazoline with the metallic derivative of an ester enolate, reducing the ester, hydrolyzing the thiazolidine moiety and hydrolyzing or oxidizing the resultant compound. Intermediates obtained in the preparation of biotin by the above process and alternate procedures for preparing said intermediates are also presented. A novel process for preparation of d-biotin is also given.
Patent IE-33571-L (IE)
Title: Preparation of cephalosporins
IPC: C07F7/18
Filed: 1969-08-15
Abstract: 1,269,697. Silylated cephalosporin derivatives. ELI LILLY & CO. 22 Aug., 1969 [23 Aug., 1968], No. 42066/69. Heading C2A. [Also in Division C3] Novel silylated cephalosporin derivatives of Formula VI wherein R<SP>11</SP> is hydrogen or acetoxy, and R<SP>1</SP>, R<SP>2</SP> and R<SP>3</SP> are each hydrogen or a C 1 to C 8 hydrocarbon radical free from aliphatic unsaturation, with not more than two of R<SP>1</SP> , R<SP>2</SP> and R<SP>3</SP> bonded to the same silicon atom being hydrogen, and R<SP>10</SP> is hydrogen or the group: are prepared by reacting 7-aminocephalosporanic acid or 7-amino-desacetoxycephalosporanic acid or a salt thereof, with a mono- or bissilylamide of one of the Formulµ I to V wherein R<SP>1</SP>, R<SP>2</SP> and R<SP>3</SP> are as defined above; R<SP>5</SP> and R<SP>9</SP> are each hydrogen or C 1 to C 8 hydrocarbon free from aliphatic unsaturation, R<SP>8</SP> is C 1 to C 8 hydrocarbon free from aliphatic unsaturation; each of R<SP>4</SP>, R<SP>6</SP> and R<SP>7</SP> is hydrogen or C 1 to C 8 hydrocarbon free from aliphatic unsaturation, or R<SP>6</SP> and R<SP>7</SP> together with the common nitrogen complete a heterocyclic ring containing 5 to 6 ring-forming atoms, one of which can be oxygen para to the nitrogen, or 4 to 6 ring-forming carbons provided that R<SP>6</SP> and R<SP>7</SP> together contain not more than 18 carbons and that if R<SP>6</SP> is alkyl with tert. carbon bonded to the nitrogen then R<SP>7</SP> is hydrogen; or R<SP>4</SP> and R<SP>6</SP> together with the attached nitrogens and the carbonyl group form a heterocyclic ring containing 5 to 6 ring-forming atoms and 2 to 3 methylene ring-forming carbon atoms; and Y is a C 3 to C 18 alkylene group with a 3 to 5 carbon chain between the nitrogen and the carbonyl group to which Y is bonded, the reaction being effected in an anhydrous aprotic solvent at - 25 to +50 C. The invention includes a composition comprising (a) a compound of Formula VI above, (b) a silylamide of one of Formulµ I to V above and (c) an anhydrous solvent for (a) and (b) of which the molecules do not contain Zerewitinoff hydrogen. The silylated cephalosporins may be converted to known antibiotically active cephalosporins by reacting with an appropriate acylating agent to give the corresponding N-acylated silyl ester which is treated with a C 1 to C 6 alkanol to give the required cephalosporin which is recovered from the solution preferably as the Na or K salt. Cephalothin, cephaloglycin and cephalexin are prepared in this way.
[GB1269697A]